Clinical research on lower gastrointestinal cancer

The Cambridge Colorectal Cancer Group (CCCG) has broad interests including basic research in colorectal cancer cells and animal models on the cell-biological and molecular mechanisms underpinning the disease. The Group also conducts translational and clinical investigations on prognostic biomarkers, early detection and recurrence of disease, metastasis and cancer therapy. Samples from over 2,000 colorectal cancer patients are being used to create full pathological records and family histories to increase our understanding of the disease.

Current open trials in Cambridge

The table below lists the current open trials for lower gastrointestinal cancer coordinated by the Cambridge Cancer Trials Centre (last updated January 2016).

Trial name Trial description Contact
FOCUS 4 FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme Dr Hugo Ford
NSCCG National Study of Colorectal Cancer Genetics Dr Cheryl Palmer
Quantifying disease burden in patients with cancer using tumour-specific genomic rearrangements This is a prospective study using human colorectal primary tumour tissue collected at time of surgery,from which we will derive a signature for that patient’s cancer based upon the presence of specific gene rearrangements. The presence of these rearrangements will then for detected for in plasma samples using highly sensitive Q-PCR techniques, and levels will be correlated with progression-free survival and rates of relapse. Dr Ultan McDermott
If you would like further information about how to take part in any of the clinical trials listed here that are open to recruitment, please talk to your cancer specialist as patients usually need to be referred by their doctor. 

Cambridge Cancer Trials Centre contact for lower gastrointestinal (lower GI) cancer trials: Dr Hugo Ford